10 October 2014 -Vernalis plc has opened its US office in Berwyn, Pennsylvania and has strengthened its US Executive team with the appointment of Dr Pascal Borderies, as SVP Medical Affairs.
Ian Garland, CEO of Vernalis commented "We are delighted to establish our base in the US and welcome Pascal to the team. His knowledge and experience perfectly complement our current team's expertise as Vernalis continues to grow its US commercial business in preparation for the expected launch in 2015 of its first cough cold product Tuzistra™ XR."
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline.